Alkermes plc
ALKS
Peringkat dalam Saham
#2637
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Harga Saham
$43.05
Kapitalisasi Pasar
$7.22B
Perubahan (1 hari)
4.43%
Perubahan (1 tahun)
42.25%
Negara
IE
Perdagangan Alkermes plc (ALKS)
Kategori
Healthcare
Rasio P/E untuk Alkermes plc (ALKS)
Rasio P/E per October 2026 TTM: 96.97
Menurut laporan keuangan dan harga saham terbaru dari Alkermes plc, rasio P/E saat ini (TTM) adalah 96.97. Pada akhir 2023, perusahaan memiliki rasio P/E sebesar 12.96.
Riwayat rasio P/E untuk Alkermes plc dari 2000 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 96.97 | 648.25% |
| 2024 | 12.96 | -0.02% |
| 2023 | 12.96 | -147.94% |
| 2022 | -27.03 | -65.21% |
| 2021 | -77.72 | 171.95% |
| 2020 | -28.58 | 75.38% |
| 2019 | -16.29 | -50.41% |
| 2018 | -32.86 | -38.19% |
| 2017 | -53.16 | 31.61% |
| 2016 | -40.39 | -22.53% |
| 2015 | -52.14 | -81.58% |
| 2014 | -283.00 | -332.58% |
| 2013 | 121.68 | 24.42% |
| 2012 | 97.80 | -848.45% |
| 2011 | -13.07 | -52.01% |
| 2010 | -27.23 | -6.20% |
| 2009 | -29.03 | -435.13% |
| 2008 | 8.66 | -7.01% |
| 2007 | 9.32 | -95.98% |
| 2006 | 231.69 | -6.37% |
| 2005 | 247.46 | -1,391.21% |
| 2004 | -19.17 | 163.56% |
| 2003 | -7.27 | -54.08% |
| 2002 | -15.84 | -30.43% |
| 2001 | -22.76 | -85.11% |
| 2000 | -152.84 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 28.78 | -70.32% |
US
|
|
| -28.36 | -129.24% |
US
|
|
| -24.57 | -125.33% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -68.72% |
NL
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.